- Home
- ATRO vs DNTH Comparison
ATRO vs DNTH Comparison
Compare ATRO & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATRO
- DNTH
- Stock Information
- Founded
- ATRO 1968
- DNTH 2015
- Country
- ATRO United States
- DNTH United States
- Employees
- ATRO N/A
- DNTH N/A
- Industry
- ATRO Military/Government/Technical
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- ATRO Industrials
- DNTH Health Care
- Exchange
- ATRO Nasdaq
- DNTH Nasdaq
- Market Cap
- ATRO 1.2B
- DNTH 1.0B
- IPO Year
- ATRO N/A
- DNTH N/A
- Fundamental
- Price
- ATRO $39.89
- DNTH $37.16
- Analyst Decision
- ATRO Strong Buy
- DNTH Strong Buy
- Analyst Count
- ATRO 1
- DNTH 9
- Target Price
- ATRO $49.00
- DNTH $61.57
- AVG Volume (30 Days)
- ATRO 1.0M
- DNTH 945.4K
- Earning Date
- ATRO 11-05-2025
- DNTH 11-06-2025
- Dividend Yield
- ATRO N/A
- DNTH N/A
- EPS Growth
- ATRO N/A
- DNTH N/A
- EPS
- ATRO N/A
- DNTH N/A
- Revenue
- ATRO $822,852,000.00
- DNTH $4,854,000.00
- Revenue This Year
- ATRO $9.05
- DNTH N/A
- Revenue Next Year
- ATRO $6.88
- DNTH N/A
- P/E Ratio
- ATRO N/A
- DNTH N/A
- Revenue Growth
- ATRO 10.99
- DNTH 17.87
- 52 Week Low
- ATRO $14.13
- DNTH $13.37
- 52 Week High
- ATRO $46.61
- DNTH $38.59
- Technical
- Relative Strength Index (RSI)
- ATRO 58.68
- DNTH 83.51
- Support Level
- ATRO $39.24
- DNTH $22.81
- Resistance Level
- ATRO $46.61
- DNTH $24.81
- Average True Range (ATR)
- ATRO 2.09
- DNTH 2.67
- MACD
- ATRO 0.37
- DNTH 1.45
- Stochastic Oscillator
- ATRO 39.08
- DNTH 90.94
About ATRO Astronics Corporation
Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.